Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.
Latest From Pricing Debate
A new methodology for evaluating the benefits of new medicines aims to make funding decisions more transparent and structured. It could also offer an alternative to the way health technology appraisals reflect value.
Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.
Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.
The Turkish government plans to fix the country’s tamoxifen drug shortage problem by allowing by a local company to manufacture the product.
Strengthening Brazil’s policy on orphan drugs would help stem the number of court cases brought by patients to access medicines, says Alexion.
The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.
Drug pricing critic Steve Miller, chief medical officer with Express Scripts, praises Novartis' gene therapy pricing and promotes benefits of amortized payments tied to outcomes.
Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.
Estimate in JAMA paper is significantly lower than often-cited $2.6bn in research and development costs projected in a 2014 study by Tufts Center for the Study of Drug Development.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.